- Keywords > cost-effectiveness - medicines
- Keywords > generic substitution policy - prices
- Keywords > innovation - availability, affordability and cost-effectiveness
- Keywords > medical device management
- Keywords > medicines expenditure - priorities
- Keywords > medicines strategy
- Keywords > national pharmaceutical expenditures - management
- Keywords > price - control
- Keywords > prices / pricing policy
- Keywords > value based pricing - clinical relevance/cost effectiveness
(2015; 76 pages)
NMSF, 2015. Value for Money: Proposed Measures to Improve Health Outcomes from Expenditure on Medicines and Health Technologies in Sudan. National Medical Supplies Fund, Khartoum Sudan
While advances in health technology over the last several decades have greatly improved life span and welfare in society, it is often perceived that the cost of these innovations has not been adequately offset by their benefit. Increased health care budgets in most countries have emphasized the need to demonstrate value for money from expenditure on health technologies. This paper aims to establish measures that secure the provision of safe and effective medicines to Sudanese patients at reasonable prices and that encourage the efficient and competitive supply of medicines.
As a ‘desk-based’ paper, the major source was published literature and the key strategies identified in the literature review (see list at the end of the document) have been modified to fit the Sudan context. The strategies that are advocated throughout the paper are based on the premise that the best value for money does not necessarily mean the lowest initial price option, but rather the best return on the money spent to meet the population’s need for medicines and other medical technologies.
This paper identifies a number of strategies, which should be in place to ensure that expenditure on medicines provides value for money. These strategies include: use of therapeutically equivalent generic medicines; applying pharmacoeconomics; selection of medicines; control of medicine prices; rational use of medicines; improving adherence to treatment regimes; prohibiting unethical promotion by pharmaceutical companies; reducing medication errors and adverse drug reactions; promoting responsible self-medication; clinical pharmacy services; pooled procurement; safety, efficacy and quality of medicines; and management of medical devices.